To prospectively evaluate the predictive value of pretreatment histogram analysis of apparent diffusion coefficients (ADC) at whole body diffusion-weighted imaging (WB-DWI/MRI) for patient outcome in primary ovarian cancers.
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Aim
To prospectively evaluate the predictive value of pretreatment histogram analysis of apparent diffusion coefficients (ADC) at whole body diffusion-weighted imaging (WB-DWI/MRI) for patient outcome in primary ovarian cancers.
Methods
Institutional review board approval and informed consent were obtained for this prospective study. Forty-four women diagnosed with FIGO stage III or IV ovarian carcinoma underwent 3-Tesla WB-DWI/MRI using 2 b-values (b=0-1000 s/mm 2 ), T2-weighted and contrast-enhanced T1-weighted sequences prior to treatment. The primary tumour was delineated using semi-automated software and was analysed by using an ADC histogram approach: mean and median ADC, standard deviation (SD), coefficient of variation (CoV, SD/mean), kurtosis and skewness were calculated. Kaplan-Meier with log-rank statistics were used to correlate baseline ADC parameters to disease free survival (DFS). Effects of confounding patients-and tumour-related factors were taken into consideration using Cox proportional hazard model.
Results
5 patients underwent primary-and 39 interval debulking surgery completing 6 cycles of platinum-based chemotherapy. Survival analyses showed that lower CoV was associated with significantly longer DFS (median ± SD; 19±2 months for CoV<0.2601 versus 12±1 months for CoV>0.2601; p=0.002). After multivariable analysis, CoV remained an independent prognostic biomarker for DFS (p=0.003) when taking patient's age, FIGO stage, tumour grade and cancer antigen (CA)-125 level into consideration as clinical prognostic factors.
Conclusion
In this pilot study, pre-treatment ADC histogram analysis of primary ovarian cancer using the CoV was an independent predictive marker of DFS suggesting a correlation between tumour heterogeneity and treatment resistance. Further research should elucidate the correlation with overall survival.
